Breaking News

Financial Report: Lilly

April 24, 2014

Cymbalta and Evista patent expirations impact results


1Q Revenues: $4.7 billion (-16%)

1Q Earnings: $749.9 million (-52%)

Comments: Results were impacted by U.S. patent expirations for Cymbalta (-64% to $478.2 million) and Evista (-38% to $150.1 million). Humalog sales were up 3% to $632.7 million. Alimta sales were up 2% to $632.0 million. Cialis sales were $532.4 million, up 3%. R&D expenses were down 18% to $1.1 billion. In the quarter, the company gained approval for Cyramza for advanced or metastatic gastric cancer, and entered an agreement to acquire Novartis Animal Health for approximately $5.4 billion in cash.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks